Camlin Fine Sciences Limited (CAMLINFINE) - Net Assets
Based on the latest financial reports, Camlin Fine Sciences Limited (CAMLINFINE) has net assets worth Rs8.60 Billion INR (≈ $93.02 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs20.37 Billion ≈ $220.29 Million USD) and total liabilities (Rs11.77 Billion ≈ $127.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CAMLINFINE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs8.60 Billion |
| % of Total Assets | 42.23% |
| Annual Growth Rate | 23.37% |
| 5-Year Change | 22.66% |
| 10-Year Change | 396.43% |
| Growth Volatility | 24.48 |
Camlin Fine Sciences Limited - Net Assets Trend (2007–2025)
This chart illustrates how Camlin Fine Sciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore Camlin Fine Sciences Limited balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Camlin Fine Sciences Limited (2007–2025)
The table below shows the annual net assets of Camlin Fine Sciences Limited from 2007 to 2025. For live valuation and market cap data, see market value of Camlin Fine Sciences Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs8.75 Billion ≈ $94.60 Million |
+2.08% |
| 2024-03-31 | Rs8.57 Billion ≈ $92.68 Million |
+3.99% |
| 2023-03-31 | Rs8.24 Billion ≈ $89.12 Million |
+7.72% |
| 2022-03-31 | Rs7.65 Billion ≈ $82.74 Million |
+7.28% |
| 2021-03-31 | Rs7.13 Billion ≈ $77.12 Million |
+55.00% |
| 2020-03-31 | Rs4.60 Billion ≈ $49.76 Million |
+6.93% |
| 2019-03-31 | Rs4.30 Billion ≈ $46.53 Million |
-0.72% |
| 2018-03-31 | Rs4.33 Billion ≈ $46.87 Million |
+88.26% |
| 2017-03-31 | Rs2.30 Billion ≈ $24.89 Million |
+30.63% |
| 2016-03-31 | Rs1.76 Billion ≈ $19.06 Million |
+30.66% |
| 2015-03-31 | Rs1.35 Billion ≈ $14.59 Million |
+44.54% |
| 2014-03-31 | Rs933.04 Million ≈ $10.09 Million |
+42.70% |
| 2013-03-31 | Rs653.83 Million ≈ $7.07 Million |
+23.58% |
| 2012-03-31 | Rs529.06 Million ≈ $5.72 Million |
+13.89% |
| 2011-03-31 | Rs464.53 Million ≈ $5.02 Million |
+59.46% |
| 2010-03-31 | Rs291.32 Million ≈ $3.15 Million |
-0.03% |
| 2009-03-31 | Rs291.41 Million ≈ $3.15 Million |
+4.71% |
| 2008-03-31 | Rs278.32 Million ≈ $3.01 Million |
+39.46% |
| 2007-03-31 | Rs199.57 Million ≈ $2.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Camlin Fine Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 99635300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs996.35 Million | 11.05% |
| Common Stock | Rs187.92 Million | 2.08% |
| Other Comprehensive Income | Rs718.37 Million | 7.97% |
| Other Components | Rs7.11 Billion | 78.90% |
| Total Equity | Rs9.02 Billion | 100.00% |
Camlin Fine Sciences Limited Competitors by Market Cap
The table below lists competitors of Camlin Fine Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Accent Group Ltd
AU:AX1
|
$263.73 Million |
|
Master Tec Group Berhad
KLSE:0295
|
$263.77 Million |
|
ARYZTA UN.ADR 1/2 SF -02
F:YZAU
|
$263.85 Million |
|
Immobel
BR:IMMO
|
$263.85 Million |
|
Asuransi Tugu Pratama Indonesia Tbk PT
JK:TUGU
|
$263.55 Million |
|
Xinjiang Zhundong Petroleum
SHE:002207
|
$263.44 Million |
|
Suprema Inc
KQ:236200
|
$263.44 Million |
|
Roche Bobois
PA:RBO
|
$263.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Camlin Fine Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,647,508,000 to 9,016,730,000, a change of 369,222,000 (4.3%).
- Net loss of 1,390,459,000 reduced equity.
- Share repurchases of 2,231,263,000 reduced equity.
- New share issuances of 2,231,263,000 increased equity.
- Other comprehensive income decreased equity by 571,275,000.
- Other factors increased equity by 2,330,956,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-1.39 Billion | -15.42% |
| Share Repurchases | Rs2.23 Billion | -24.75% |
| Share Issuances | Rs2.23 Billion | +24.75% |
| Other Comprehensive Income | Rs-571.27 Million | -6.34% |
| Other Changes | Rs2.33 Billion | +25.85% |
| Total Change | Rs- | 4.27% |
Book Value vs Market Value Analysis
This analysis compares Camlin Fine Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 34.67x to 2.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-03-31 | Rs3.66 | Rs126.94 | x |
| 2008-03-31 | Rs3.60 | Rs126.94 | x |
| 2009-03-31 | Rs3.34 | Rs126.94 | x |
| 2010-03-31 | Rs3.30 | Rs126.94 | x |
| 2011-03-31 | Rs4.99 | Rs126.94 | x |
| 2012-03-31 | Rs5.63 | Rs126.94 | x |
| 2013-03-31 | Rs6.94 | Rs126.94 | x |
| 2014-03-31 | Rs9.88 | Rs126.94 | x |
| 2015-03-31 | Rs14.09 | Rs126.94 | x |
| 2016-03-31 | Rs18.25 | Rs126.94 | x |
| 2017-03-31 | Rs20.93 | Rs126.94 | x |
| 2018-03-31 | Rs33.77 | Rs126.94 | x |
| 2019-03-31 | Rs30.59 | Rs126.94 | x |
| 2020-03-31 | Rs33.22 | Rs126.94 | x |
| 2021-03-31 | Rs46.50 | Rs126.94 | x |
| 2022-03-31 | Rs56.16 | Rs126.94 | x |
| 2023-03-31 | Rs48.35 | Rs126.94 | x |
| 2024-03-31 | Rs52.01 | Rs126.94 | x |
| 2025-03-31 | Rs51.11 | Rs126.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Camlin Fine Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.34%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 2.24x
- Recent ROE (-15.42%) is below the historical average (7.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -9.14% | -3.88% | 0.81x | 2.89x | Rs-38.19 Million |
| 2008 | 9.41% | 3.29% | 1.18x | 2.43x | Rs-1.62 Million |
| 2009 | 8.46% | 2.35% | 1.12x | 3.23x | Rs-4.46 Million |
| 2010 | 4.17% | 0.86% | 1.17x | 4.13x | Rs-16.91 Million |
| 2011 | 15.30% | 4.24% | 0.91x | 3.97x | Rs24.63 Million |
| 2012 | 7.17% | 1.13% | 1.17x | 5.40x | Rs-14.98 Million |
| 2013 | 23.09% | 4.04% | 1.01x | 5.65x | Rs85.57 Million |
| 2014 | 30.77% | 5.64% | 1.37x | 3.99x | Rs193.83 Million |
| 2015 | 40.80% | 9.86% | 1.30x | 3.19x | Rs415.41 Million |
| 2016 | 20.33% | 7.32% | 1.01x | 2.74x | Rs182.02 Million |
| 2017 | -5.26% | -2.11% | 0.79x | 3.16x | Rs-324.33 Million |
| 2018 | -7.99% | -4.15% | 0.70x | 2.74x | Rs-667.59 Million |
| 2019 | 0.16% | 0.07% | 0.81x | 2.93x | Rs-365.11 Million |
| 2020 | 7.52% | 2.91% | 0.84x | 3.06x | Rs-99.95 Million |
| 2021 | 7.92% | 4.32% | 0.80x | 2.30x | Rs-133.77 Million |
| 2022 | 8.11% | 4.32% | 0.78x | 2.41x | Rs-141.16 Million |
| 2023 | 6.36% | 3.10% | 0.82x | 2.51x | Rs-298.31 Million |
| 2024 | -10.73% | -5.82% | 0.82x | 2.26x | Rs-1.79 Billion |
| 2025 | -15.42% | -8.34% | 0.82x | 2.24x | Rs-2.29 Billion |
Industry Comparison
This section compares Camlin Fine Sciences Limited's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $8,233,598,031
- Average return on equity (ROE) among peers: 14.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Camlin Fine Sciences Limited (CAMLINFINE) | Rs8.60 Billion | -9.14% | 1.37x | $263.70 Million |
| Aarti Industries Limited (AARTIIND) | $16.55 Billion | 20.11% | 1.65x | $1.99 Billion |
| Aarti Surfactants Limited (AARTISURF) | $1.11 Billion | 1.88% | 1.36x | $37.34 Million |
| ABM International Limited (ABMINTLLTD) | $161.33 Million | 4.08% | 2.02x | $4.23 Million |
| Advanced Enzyme Technologies Limited (ADVENZYMES) | $1.66 Billion | 30.02% | 1.39x | $420.87 Million |
| Aether Industries Limited (AETHER) | $22.26 Billion | 7.12% | 0.19x | $1.68 Billion |
| Akzo Nobel India Limited (AKZOINDIA) | $9.20 Billion | 20.25% | 0.96x | $1.45 Billion |
| Alkali Metals Limited (ALKALI) | $528.67 Million | 5.51% | 1.00x | $7.38 Million |
| Alkyl Amines Chemicals Limited (ALKYLAMINE) | $980.47 Million | 17.95% | 1.88x | $838.56 Million |
| Ami Organics Limited (AMIORG) | $576.82 Million | 32.06% | 1.70x | $1.18 Billion |
| Anupam Rasayan India Limited (ANURAS) | $29.31 Billion | 4.39% | 0.57x | $1.65 Billion |
About Camlin Fine Sciences Limited
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate… Read more